This study identified six common genomic biomarkers (cGBs) - MYC, MMP9, IL6, THBS1, SPP1, and CXCL1-that differentiate patients with T2D, HCC, and CRC from control groups. This evidence concerns the gene CXCL1 and hepatocellular carcinoma.